| Compound | Asimicin |
| NPACT-Id | NPACT00292 |
| IUPAC | 4-[8,13-dihydroxy-13-[5-[5-(1-hydroxyundecyl)oxolan-2-yl]oxolan-2-yl]tridecyl]-2-methyl-2H-furan-5-one |
| Synonyms | - |
| PubChem Id | 183613 |
| Class | Polyketides |
| In-vitro anticancer activity | 8 cancer cell lines |
| In-Vivo anticancer activity | No |
| Targets | NOX1 | All | |
| Properties | Physical Elemental Topological |
| InChi Key | MBABCNBNDNGODA-DACSEHCNSA-N |
| InChi | 1S/C37H66O7/c1-3-4-5-6-7-11-14-17-20-31(39)33-22-24-35(43-33)36-25-23-34(44-36)32(40)21-18-15-12-9-8-10-13-16-19-30(38)27-29-26-28(2)42-37(29)41/h26,28,30-36,38-40H,3-25,27H2,1-2H3/t28-,30+,31-,32+,33+,34?,35+,36+/m0/s1 |
| SMILES | O1[C@@H]([C@@H]2O[C@H](CC2)[C@@H](O)CCCCCCCCCC)CC[C@H]1[C@H](O)CCCCCCCCCC[C@@H](O)CC1=C[C@@H](OC1=O)C |
|
SMART | [H]O[C@@]([H])(C([H])([H])C1=C([H])[C@@]([H])(OC1=O)C([H])([H])[H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[C@@]([H])(O[H])[C@@]1([H])O[C@]([H])(C([H])([H])C1([H])[H])[C@]1([H])O[C@]([H])(C([H])([H])C1([H])[H])[C@@]([H])(O[H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] |
| CAS No. | 123123-32-0 |
|
Structure
Download | 
|
| Cross Refrence in other databases |
| Super Natural | - |
| CTD | C061022 |
| HIT | - |
| NCI-60 GI50 data | - |
| Suppliers | ABI Chem, |
| Drug-Likeliness Filters | Lipinski's rule of five | No |
| Ghose filter | No |
| Veber filter | No |
| Muegge Filter | No |
| Similarity Search | Human metabolite database | FDA approved drugs |